110508-92-4

Basic information

• Product Name: delapril
• Synonyms: Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-D-alanyl]-, (R)-
• CAS NO: 110508-92-4
• Molecular Formula: C26H32 N2 O5
• Molecular Weight: 452.54
• Mol File: 110508-92-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: delapril(CAS DataBase Reference)
• NIST Chemistry Reference: delapril(110508-92-4)
• EPA Substance Registry System: delapril(110508-92-4)

Safety Data

• Hazardous Substances Data: 110508-92-4(Hazardous Substances Data)

Upstream product

• 83356-18-7 N-(2,3-dihydro-1 H-inden-2-yl)-glycine benzyl ester hydrochloride 
• 80828-26-8 N-[1-(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine hydrochloride 
• 119543-19-0 delapril benzyl ester 

Related news

Safety and efficacy study of delapril (cas 110508-92-4) versus enalapril in patients with congestive heart failure08/22/2019

The results after the first 6 months of the 1 -year treatment of this multicenter, randomized, open, parallel-group design study of delapril versus enalapril in patients with congestive heart failure (CHF), New York Heart Association (NYHA) classes II and III, are presented. The initial dose of ...detailed

Congestive heart failure in elderly patients: Controlled study of delapril (cas 110508-92-4) versus captopril08/21/2019

In this controlled trial, 30 elderly patients with congestive heart failure, New York Heart Association (NYHA) classes II and III, were randomly assigned to treatment with captopril 25 mg three times daily or delapril 15 mg twice daily. At the end of an 8-week treatment period, clinical symptoms...detailed

delapril (cas 110508-92-4) slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits08/20/2019

The renin–angiotensin system is an important modulator of arterial blood pressure and inhibitors of the angiotensin-converting enzyme (ACE-Is) and are currently used in the treatment of hypertension. The pleiotropic actions exerted by angiotensin II (AngII) on the functionality of the vessel wa...detailed

delapril (cas 110508-92-4) versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy08/19/2019

Thirty-nine hypertensive patients with type 2 diabetes mellitus were followed under long-term treatment (mean, 20.7 months) with manidipine hydrochloride, a Ca antagonist, or delapril hydrochloride, an ACE inhibitor, at nine institutions. Both the treatments showed similar antihypertensive effec...detailed

Effects of the fixed combination of manidipine plus delapril (cas 110508-92-4) in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial08/18/2019

Background: Failure to achieve good blood pressure (BP) control is probably the most important reason for high rates of morbidity and mortality in patients with hypertension. Combination therapy has been shown to increase the percentage of patients in whom BP control is achieved. One combination...detailed

Efficacy and safety of delapril (cas 110508-92-4) plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial08/17/2019

Background:The use of coombination therapy is required to achieve blood pressure targets in 40% to 75% of patients with hypertension. There have been few studies comparing the efficacy and tolerability of the new fixed combination of the angiotensin-converting enzyme (ACE) inhibitor delapril 30 ...detailed

Effect on the development of ankle edema of adding delapril (cas 110508-92-4) to manidipine in patients with mild to moderate essential hypertension: A three-way crossover study08/16/2019

Background:Use of the combination of an angiotensinconverting enzyme inhibitor (ACEI) and a calcium channel blocker (CCB) is considered a rational approach in patients whose hypertension is not controlled by monotherapy, providing better blood pressure (BP) control than the individual components...detailed

Rationale for use of the fixed combination of delapril (cas 110508-92-4) and manidipine in the treatment of hypertension in patients with diabetes mellitus08/15/2019

Background: The fixed combination of the angiotensin-converting enzyme (ACE) inhibitor delapril and the dihydropyridine calcium channel blocker manidipine is a new oral, QD antihypertensive regimen that may have a role in the management of hypertension in patients with diabetes mellitus (DM).Obj...detailed

delapril (cas 110508-92-4) versus enalapril in patients with congestive heart failure08/14/2019

This 12-month, multicenter, randomized, parallel-group study compared the effects of delapril with enalapril in 179 patients with congestive heart failure, New York Heart Association (NYHA) classes II and III. The initial doses of delapril (7.5 mg twice daily [BID]) and enalapril (2.5 mg BID) co...detailed

Original ArticleDissolution method for delapril (cas 110508-92-4) and manidipine combination tablets based on an absorption profile of manidipine☆08/13/2019

The present study describes the development and validation of a dissolution method for delapril (DEL) and manidipine (MAN) combination tablets, using a simulated absorption profile based on in vivo data for MAN. The suitable in vitro dissolution profile for this formulation was obtained using 90...detailed

Relevant articles and documents

PROCESS FOR THE PREPARATION OF AMIDES OF N-[1-(S)-(ETHOXYCARBONYL)-3-PHENYLPROPYL]-L-ALANINE

A process for the production of amides of N-[1-(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine is described. The process can be used for the production of key intermediates and finally the ACE inhibitors such as Ramipril, Enalapril, Quinapril, Trandolapril, Delapril and Moexipril starting from N-[1-(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine by the reaction with the appropriate amines.